Analyzing CytoDyn (OTCMKTS:CYDY) and Enliven Therapeutics (NASDAQ:ELVN)

CytoDyn (OTCMKTS:CYDY) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Analyst Ratings

This is a breakdown of recent ratings and price targets for CytoDyn and Enliven Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytoDyn	0	0	0	0	0.00
Enliven Therapeutics	1	0	4	0	2.60

Enliven Therapeutics has a consensus price target of $41.00, suggesting a potential upside of 53.50%. Given Enliven Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than CytoDyn.

Valuation and Earnings

This table compares CytoDyn and Enliven Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytoDyn	N/A	N/A	$3.74 million	($0.03)	-8.61
Enliven Therapeutics	N/A	N/A	-$89.02 million	($1.84)	-14.52

Enliven Therapeutics is trading at a lower price-to-earnings ratio than CytoDyn, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

CytoDyn has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Institutional & Insider Ownership

5.1% of CytoDyn shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 1.0% of CytoDyn shares are owned by insiders. Comparatively, 25.9% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares CytoDyn and Enliven Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CytoDyn	N/A	N/A	-175.37%
Enliven Therapeutics	N/A	-24.88%	-23.96%

Summary

Enliven Therapeutics beats CytoDyn on 6 of the 11 factors compared between the two stocks.

About CytoDyn

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.